Cervix Cancer in Sub-Saharan Africa: An Assessment of Cervical Cancer Management.


Journal

JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170

Informations de publication

Date de publication:
02 2021
Historique:
entrez: 2 2 2021
pubmed: 3 2 2021
medline: 6 8 2021
Statut: ppublish

Résumé

Underdeveloped nations carry the burden of most cervical cancer, yet access to adequate treatment can be challenging. This report assesses the current management of cervical cancer in sub-Saharan Africa to better understand the needs of underdeveloped nations in managing cervical cancer. A pre- and postsurvey was sent to all centers participating in the Cervical Cancer Research Network's 4th annual symposium. The pre- and postsurvey evaluated human papillomavirus and HIV screening, resources available for workup and/or treatment, treatment logistics, outcomes, and enrollment on clinical trials. Descriptive analyses were performed on survey responses. Twenty-nine centers from 12 sub-Saharan countries saw approximately 300 new cases of cervical cancer yearly. Of the countries surveyed, 55% of countries had a human papillomavirus vaccination program and 30% (range, 0%-65%) of women in each region were estimated to have participated in a cervical cancer screening program. In the workup of patients, 43% of centers had the ability to obtain a positron emission tomography and computed tomography scan and 79% had magnetic resonance imaging capabilities. When performing surgery, 88% of those centers had a surgeon with an expertise in performing oncological surgeries. Radiation therapy was available at 96% of the centers surveyed, and chemotherapy was available in 86% of centers. Clinical trials were open at 4% of centers. There have been significant advancements being made in screening, workup, and management of patients with cervical cancer in sub-Saharan Africa; yet, improvement is still needed. Enrollment in clinical trials remains a struggle. Participants would like to enroll patients on clinical trials with Cervical Cancer Research Network's continuous support.

Identifiants

pubmed: 33529076
doi: 10.1200/GO.20.00079
pmc: PMC8081497
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-182

Subventions

Organisme : NCI NIH HHS
ID : K08 CA228631
Pays : United States

Références

J Infect Dis. 2004 Oct 15;190(8):1413-21
pubmed: 15378433
Gynecol Oncol Rep. 2016 Nov 25;19:5-9
pubmed: 28004030
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
Vaccine. 2015 May 7;33 Suppl 1:A167-73
pubmed: 25919157
Vaccines (Basel). 2018 Sep 08;6(3):
pubmed: 30205561
Gynecol Oncol. 2016 Sep;142(3):413-9
pubmed: 27178725
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Semin Radiat Oncol. 2017 Apr;27(2):184-188
pubmed: 28325246
Clin Transl Oncol. 2011 Jul;13(7):431-3
pubmed: 21775268
J Glob Oncol. 2017 Feb 8;3(5):666-670
pubmed: 29094103
J Clin Oncol. 2019 Nov 20;37(33):3124-3131
pubmed: 31449470
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Gynecol Oncol. 1999 May;73(2):177-83
pubmed: 10329031
Vaccine. 2015 May 7;33 Suppl 1:A174-81
pubmed: 25919158

Auteurs

Lindsay M Burt (LM)

Radiation Oncology Department, University of Utah, Huntsman Cancer Institute, Salt Lake City, UH.

Mary McCormak (M)

University College Hospital London, London, United Kingdom.

Fabrice Lecuru (F)

Georges Pompidou European Hospital, Paris, France.

Daniel M Kanyike (DM)

Uganda Cancer Institute, Kampala, Uganda.

Memory Bvochora-Nsingo (M)

Gaborone Private Hospital, Gaborone, Botswana.

Ntokozo Ndlovu (N)

University of Zimbabwe College of Health Sciences, Parirenyatwa Hospital Harare, Harare, Zimbabwe.

Aba A Scott (AA)

Korle Bu Teaching Hospital, Accra, Ghana.

Rose I Anorlu (RI)

University of Lagos, Lagos University Teaching Hospital, Lagos, Nigeria.

Vinay Sharma (V)

Charlotte Maxeke Johannesburg Academic Hospital, University of Witwatersrand, Park Town, South Africa.

Marie Plante (M)

L'Hotel Dieu de Quebec, Quebec, Canada.

Catherine Nyongesa (C)

Kenyatta National Hospital, Texas Centre, Nairobi, Kenya.

Wondemagegnehu Tigeneh (W)

Addis Ababa University College of Health Sciences, Addis Ababa, Ethiopia.

Nazia Fakie (N)

University of Cape Town, Cape Town, South Africa.

Gita Suneja (G)

Radiation Oncology Department, University of Utah, Huntsman Cancer Institute, Salt Lake City, UH.

David K Gaffney (DK)

Radiation Oncology Department, University of Utah, Huntsman Cancer Institute, Salt Lake City, UH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH